<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>2</IssueIDStart>
          <IssueIDEnd>2</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>6</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art24">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>72488</ArticleID>
            <ArticleDOI>10.1208/aapsj070249</ArticleDOI>
            <ArticleSequenceNumber>24</ArticleSequenceNumber>
            <ArticleTitle Language="En">Challenges in the transition to model-based development</ArticleTitle>
            <ArticleFirstPage>E488</ArticleFirstPage>
            <ArticleLastPage>E495</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>3</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>5</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>2</IssueIDStart>
              <IssueIDEnd>2</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Thaddeus</GivenName>
                  <GivenName>H.</GivenName>
                  <FamilyName>Grasela</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(716) 633-3463</Phone>
                  <Fax>(716) 633-7404</Fax>
                  <Email>ted.grasela@cognigencorp.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Jill</GivenName>
                  <FamilyName>Fiedler-Kelly</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Cynthia</GivenName>
                  <GivenName>A.</GivenName>
                  <FamilyName>Walawander</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Joel</GivenName>
                  <GivenName>S.</GivenName>
                  <FamilyName>Owen</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Brenda</GivenName>
                  <GivenName>B.</GivenName>
                  <FamilyName>Cirincione</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Kathleen</GivenName>
                  <GivenName>E.</GivenName>
                  <FamilyName>Reitz</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Elizabeth</GivenName>
                  <GivenName>A.</GivenName>
                  <FamilyName>Ludwig</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Julie</GivenName>
                  <GivenName>A.</GivenName>
                  <FamilyName>Passarell</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Charles</GivenName>
                  <GivenName>W.</GivenName>
                  <FamilyName>Dement</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>Cognigen Corp</OrgName>
                <OrgAddress>
                  <Street>395 Youngs Road</Street>
                  <Postcode>14221-5831</Postcode>
                  <City>Buffalo</City>
                  <State>NY</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>University at Buffalo</OrgDivision>
                <OrgName>The State University at New York</OrgName>
                <OrgAddress>
                  <City>Buffalo</City>
                  <State>NY</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>Practitioners of the art and science of pharmacometrics are well aware of the considerable effort required to successfully complete modeling and simulation activities for drug development programs. This is particularly true because of the current, ad hoc implementation wherein modeling and simulation activities are piggybacked onto traditional development programs. This effort, coupled with the failure to explicitly design development programs around modeling and simulation, will continue to be an important obstacle, to the successful transition to model-based drug development. Challenges with timely data availability, high data discard rates, delays in completing modeling and simulation activities, and resistance of development teams to the use of modeling and simulation in decision making are all symptoms of an immature process capability for performing modeling and simulation.</Para>
              <Para>A process that will fulfill the promise of model-based development will require the development and deployment of three critical elements. The first is the infrastructure—the data definitions and assembly processes that will allow efficient pooling of data across trials and development programs. The second is the process itself—developing guidelines for deciding when and where modeling and simulation should be applied and the criteria for assessing performance and impact. The third element concerns the organization and culture—the establishment of truly integrated, multidisciplinary, and multiorganizational development teams trained in the use of modeling and simulation in decision-making. Creating these capabilities, infrastructure, and incentivizations are critical to realizing the full value of modeling and simulation in drug development.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>pharmacometrics</Keyword>
              <Keyword>model-based development</Keyword>
              <Keyword>real-time data assembly</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 5, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_72488.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TH</Initials>
                    <FamilyName>Grasela</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibAuthorName>
                  <Year>1984</Year>
                  <ArticleTitle Language="En">Population pharmacokinetics of procainamide from routine clinical data</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>545</FirstPage>
                  <LastPage>554</LastPage>
                  <Occurrence Type="PID">
                    <Handle>6509861</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-198409060-00004</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaL2MXnt1egug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1984;9:545–554.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibBook>
                  <BibEditorName>
                    <Initials>SL</Initials>
                    <FamilyName>Beal</FamilyName>
                  </BibEditorName>
                  <BibEditorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <Year>1998</Year>
                  <BookTitle>NONMEM Users Guides</BookTitle>
                  <PublisherName>University of California at San Francisco</PublisherName>
                  <PublisherLocation>San Francisco</PublisherLocation>
                </BibBook>
                <BibUnstructured>Beal SL, Sheiner LB, eds.<Emphasis Type="Italic">NONMEM Users Guides</Emphasis>. San Francisco: University of California at San Francisco; 1998.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>U. S. Department of Health and Human Services</InstitutionalAuthorName>
                  <Year>2004</Year>
                  <BookTitle>Challenge and Opportunity on the Critical Path to New Medical Products</BookTitle>
                  <PublisherName>Food and Drug Administration</PublisherName>
                  <PublisherLocation>Washington, DC</PublisherLocation>
                </BibBook>
                <BibUnstructured>U. S. Department of Health and Human Services.<Emphasis Type="Italic">Challenge and Opportunity on the Critical Path to New Medical Products</Emphasis>. Washington, DC: Food and Drug Administration; 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Learning versus confirming in clinical drug development</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>275</FirstPage>
                  <LastPage>291</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9084453</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0009-9236(97)90160-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK2s3jvVWitQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1997;61:275–291.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>Data on file. Congnigen Corporation, 395 Youngs Rd, Buffalo, NY 14221.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Antal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TH</Initials>
                    <FamilyName>Grasela</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RB</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <Year>1989</Year>
                  <ArticleTitle Language="En">An evaluation of population pharmacokinetics in therapeutic trials. Part IIO Prospective data collection versus retrospective data assembly</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>46</VolumeID>
                  <FirstPage>552</FirstPage>
                  <LastPage>559</LastPage>
                  <Occurrence Type="PID">
                    <Handle>2684474</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3c%2FlvFSkug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/clpt.1989.185</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Antal EJ, Grasela TH Jr, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part IIO Prospective data collection versus retrospective data assembly.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1989;46:552–559.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>VD</Initials>
                    <FamilyName>Schmith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Fiedler-Kelly</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Phillips</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TH</Initials>
                    <FamilyName>Grasela</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Prospective use of population pharmacokinetics/ pharmacodynamics in the development of cisatracurium</ArticleTitle>
                  <JournalTitle>Pharm Res.</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>91</FirstPage>
                  <LastPage>97</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9034227</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1012015719694</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2sXhsFagsrg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Prospective use of population pharmacokinetics/ pharmacodynamics in the development of cisatracurium.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1997;14:91–97.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TH</Initials>
                    <FamilyName>Grasela</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Antal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Fiedler-Kelly</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">An automated drug concentration screening and quality assurance program for clinical trials</ArticleTitle>
                  <JournalTitle>Drug Inf J.</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>273</FirstPage>
                  <LastPage>279</LastPage>
                </BibArticle>
                <BibUnstructured>Grasela TH, Antal EJ, Fiedler-Kelly J, et al. An automated drug concentration screening and quality assurance program for clinical trials.<Emphasis Type="Italic">Drug Inf J.</Emphasis> 1999;33:273–279.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>FDA</InstitutionalAuthorName>
                  <Year>1999</Year>
                  <BookTitle>Guidance for Industry:<Emphasis Type="Italic">Population Pharmacokinetics</Emphasis>
                  </BookTitle>
                  <PublisherName>Food and Drug Administration</PublisherName>
                  <PublisherLocation>Washington, DC</PublisherLocation>
                </BibBook>
                <BibUnstructured>FDA. Guidance for Industry:<Emphasis Type="Italic">Population Pharmacokinetics</Emphasis>. Washington, DC: Food and Drug Administration; 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Stewart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PN</Initials>
                    <FamilyName>Allison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Putting a price on biotechnology</ArticleTitle>
                  <JournalTitle>Nature Biotechnology</JournalTitle>
                  <VolumeID>19</VolumeID>
                  <FirstPage>813</FirstPage>
                  <LastPage>817</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11533634</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nbt0901-813</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmvVWqsr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stewart JJ, Allison PN Johnson RS. Putting a price on biotechnology.<Emphasis Type="Italic">Nature Biotechnology</Emphasis>. 2001;19:813–817.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
